{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:52:07Z","timestamp":1791946327726,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82102133"],"award-info":[{"award-number":["No.82102133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13905-7","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T19:45:50Z","timestamp":1742586350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non\u2013small cell lung cancer using 18F-FDG PET radiomics features of primary tumour and lymph nodes"],"prefix":"10.1186","volume":"25","author":[{"given":"Xingbiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wengui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"13905_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. Guide to cancer immunotherapy: from T cell basic T-cell science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"13905_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as a first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicenter, randomized, open-label, phase 3 trial. Lancet Oncol. 2019;20:924\u201337.","journal-title":"Lancet Oncol"},{"key":"13905_CR3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced, or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomized, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet"},{"key":"13905_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","volume":"10","author":"M Sorin","year":"2024","unstructured":"Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad MH, et al. Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis. JAMA Oncol. 2024;10:621\u201333.","journal-title":"JAMA Oncol"},{"key":"13905_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MCR, Harjunp\u00e4\u00e4 H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant therapy compared to adjuvant immunotherapy in eradicating metastatic disease. Cancer Discov. 2016;6:1382\u201399.","journal-title":"Cancer Discov"},{"key":"13905_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhance tumor responses to therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016;44:924\u201338.","journal-title":"Immunity"},{"key":"13905_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","volume":"169","author":"Y Lavin","year":"2017","unstructured":"Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma using paired single-cell analysis. Cell. 2017;169:750\u2013e76517.","journal-title":"Cell"},{"key":"13905_CR8","doi-asserted-by":"crossref","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomized, multicenter, open-label, phase 3 trial. Lancet. 2021;398:1344-57.","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"13905_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.annonc.2022.02.224","volume":"33","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, O\u2019Brien MER, Mauer M, Dafni U, Oselin K, Havel L, et al. VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG\/ETOP 8\u201315\u2013 PEARLS\/KEYNOTE-091 study. Ann Oncol. 2022;33:451\u20133.","journal-title":"Ann Oncol"},{"key":"13905_CR10","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann MD, Chaft JE, William WN Jr., Rusch V, Pisters KMW, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42\u201350.","journal-title":"Lancet Oncol"},{"key":"13905_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","volume":"7","author":"A Pataer","year":"2012","unstructured":"Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7:825\u201332.","journal-title":"J Thorac Oncol"},{"key":"13905_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): A review of 20,000 breast cancer patients in the National cancer data base (NCDB). Ann Surg. 2018;268:591\u2013601.","journal-title":"Ann Surg"},{"key":"13905_CR13","doi-asserted-by":"crossref","unstructured":"Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous Non\u2013Small-cell lung cancers. J Thorac Oncol. 2013;8:1084-90.","DOI":"10.1097\/JTO.0b013e31829923ec"},{"key":"13905_CR14","first-page":"1","volume":"42","author":"M Provencio","year":"2022","unstructured":"Provencio M, Calvo V, Romero A, Spicer JD, Cruz-Berm\u00fadez A. Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy. Am Soc Clin Oncol Educ Book. 2022;42:1\u201318.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"13905_CR15","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 Blockade therapies. Nat Immunol. 2020;21:1346\u201358.","journal-title":"Nat Immunol"},{"key":"13905_CR16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1\/PD-L1 checkpoint Blockade immunotherapy. Cancer Treat Rev. 2015;41:868\u201376.","journal-title":"Cancer Treat Rev"},{"key":"13905_CR17","doi-asserted-by":"publisher","first-page":"103582","DOI":"10.1016\/j.critrevonc.2022.103582","volume":"170","author":"H Deng","year":"2022","unstructured":"Deng H, Zhao Y, Cai X, Chen H, Cheng B, Zhong R, et al. PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for Early-stage non-small cell lung cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;170:103582.","journal-title":"Crit Rev Oncol Hematol"},{"key":"13905_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13000-020-0927-9","volume":"15","author":"T Krieger","year":"2020","unstructured":"Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020;15:6.","journal-title":"Diagn Pathol"},{"key":"13905_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.21037\/tlcr.2017.09.01","volume":"6","author":"BS Greenspan","year":"2017","unstructured":"Greenspan BS. Role of PET\/CT for precision medicine in lung cancer: perspective of the society of nuclear medicine and molecular imaging. Transl Lung Cancer Res. 2017;6:617\u201320.","journal-title":"Transl Lung Cancer Res"},{"key":"13905_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12957-016-0998-y","volume":"14","author":"M Higuchi","year":"2016","unstructured":"Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, et al. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. World J Surg Oncol. 2016;14:238.","journal-title":"World J Surg Oncol"},{"key":"13905_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/RLU.0000000000001934","volume":"43","author":"N Eshghi","year":"2018","unstructured":"Eshghi N, Lundeen TF, Kuo PH. Dynamic adaptation of tumor immune response with nivolumab demonstrated by 18F-FDG PET\/CT. Clin Nucl Med. 2018;43:114\u20136.","journal-title":"Clin Nucl Med"},{"key":"13905_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/cancers12051163","volume":"12","author":"G Polverari","year":"2020","unstructured":"Polverari G, Ceci F, Bertaglia V, Reale ML, Rampado O, Gallio E, et al. 18F-FDG pet parameters and radiomics features analysis in advanced Nsclc treated with immunotherapy as predictors of therapy response and survival. Cancers (Basel). 2020;12:1163.","journal-title":"Cancers (Basel)"},{"key":"13905_CR23","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","volume":"47","author":"X Tao","year":"2020","unstructured":"Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of (18)F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 Blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"13905_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441\u20136.","journal-title":"Eur J Cancer"},{"key":"13905_CR25","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.21037\/tlcr-22-158","volume":"11","author":"P Hannequin","year":"2022","unstructured":"Hannequin P, Decroisette C, Kermanach P, Berardi G, Bourbonne V. FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer. Transl Lung Cancer Res. 2022;11:2051\u201363.","journal-title":"Transl Lung Cancer Res"},{"key":"13905_CR26","doi-asserted-by":"publisher","first-page":"1350914","DOI":"10.3389\/fonc.2024.1350914","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Gong G, Sun Q, Meng X. Prediction of pCR based on clinical-radiomics model in patients with locally advanced ESCC treated with neoadjuvant chemoimmunotherapy plus chemoradiotherapy. Front Oncol. 2024;14:1350914.","journal-title":"Front Oncol"},{"key":"13905_CR27","doi-asserted-by":"publisher","first-page":"101098","DOI":"10.1016\/j.currproblcancer.2024.101098","volume":"50","author":"F Wang","year":"2024","unstructured":"Wang F, Yang H, Chen W, Ruan L, Jiang T, Cheng L, et al. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy. Curr Probl Cancer. 2024;50:101098.","journal-title":"Curr Probl Cancer"},{"key":"13905_CR28","doi-asserted-by":"publisher","first-page":"e0192859","DOI":"10.1371\/journal.pone.0192859","volume":"13","author":"S Carvalho","year":"2018","unstructured":"Carvalho S, Leijenaar RTH, Troost EGC, van Timmeren JE, Oberije C, van Elmpt W, et al. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study. PLoS ONE. 2018;13:e0192859.","journal-title":"PLoS ONE"},{"key":"13905_CR29","doi-asserted-by":"publisher","first-page":"e78552","DOI":"10.1371\/journal.pone.0078552","volume":"8","author":"S Li","year":"2013","unstructured":"Li S, Zheng Q, Ma Y, Wang Y, Feng Y, Zhao B, et al. Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of 18F-FDG PET\/CT. PLoS ONE. 2013;8:e78552.","journal-title":"PLoS ONE"},{"key":"13905_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1186\/s12885-021-08688-6","volume":"21","author":"K Nakanishi","year":"2021","unstructured":"Nakanishi K, Nakamura S, Sugiyama T, Kadomatsu Y, Ueno H, Goto M, et al. Diagnostic utility of metabolic parameters on FDG PET\/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer. BMC Cancer. 2021;21:983.","journal-title":"BMC Cancer"},{"key":"13905_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/1754-9485.12289","volume":"59","author":"X Dong","year":"2015","unstructured":"Dong X, Wu P, Sun X, Li W, Wan H, Yu J, et al. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography\/computed tomography imaging. J Med Imaging Radiat Oncol. 2015;59:338\u201345.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"13905_CR32","first-page":"CD009519","volume":"2014","author":"M Schmidt-Hansen","year":"2014","unstructured":"Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqu\u00e9 I, Figuls M, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014;2014:CD009519.","journal-title":"Cochrane Database Syst Rev"},{"key":"13905_CR33","first-page":"185","volume":"7","author":"S Montemui\u00f1o Mu\u00f1iz","year":"2021","unstructured":"Montemui\u00f1o Mu\u00f1iz S, Marcos S\u00e1nchez S, Calzas Rodr\u00edguez J, Losada Vila B, Llorente Herrero E, Hisado D\u00edaz MD, et al. Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer. J Clin Transl Res. 2021;7:185\u201398.","journal-title":"J Clin Transl Res"},{"key":"13905_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41698-020-00135-2","volume":"4","author":"Y Ling","year":"2020","unstructured":"Ling Y, Li N, Li L, Guo C, Wei J, Yuan P, et al. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. NPJ Precis Oncol. 2020;4:32.","journal-title":"NPJ Precis Oncol"},{"key":"13905_CR35","doi-asserted-by":"publisher","first-page":"pkae021","DOI":"10.1093\/jncics\/pkae021","volume":"8","author":"NA Waser","year":"2024","unstructured":"Waser NA, Quintana M, Schweikert B, Chaft JE, Berry L, Adam A, et al. Pathological response in resectable non-small cell lung cancer: A systematic literature review and meta-analysis. JNCI Cancer Spectr. 2024;8:pkae021.","journal-title":"JNCI Cancer Spectr"},{"key":"13905_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","volume":"15","author":"S Gao","year":"2020","unstructured":"Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15:816\u201326.","journal-title":"J Thorac Oncol"},{"key":"13905_CR37","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","volume":"21","author":"CA Shu","year":"2020","unstructured":"Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant Atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786\u201395.","journal-title":"Lancet Oncol"},{"issue":"Suppl 33","key":"13905_CR38","doi-asserted-by":"publisher","first-page":"S3930","DOI":"10.21037\/jtd.2018.09.129","volume":"10","author":"EY Kim","year":"2018","unstructured":"Kim EY, Kim YS, Park I, Ahn HK, Lee HY, Kim JH. Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy. J Thorac Dis. 2018;10(Suppl 33):S3930\u20132.","journal-title":"J Thorac Dis"},{"key":"13905_CR39","doi-asserted-by":"publisher","first-page":"1996000","DOI":"10.1080\/2162402X.2021.1996000","volume":"10","author":"ZR Zhao","year":"2021","unstructured":"Zhao ZR, Yang CP, Chen S, Yu H, Lin YB, Lin YB, et al. Phase 2 trial of neoadjuvant Toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021;10:1996000.","journal-title":"Oncoimmunology"},{"key":"13905_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2023.02.001","volume":"178","author":"F Zhuang","year":"2023","unstructured":"Zhuang F, Haoran E, Huang J, Wu J, Xu L, Zhang L, et al. Utility of 18F-FDG PET\/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. Lung Cancer. 2023;178:20\u20137.","journal-title":"Lung Cancer"},{"key":"13905_CR41","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers14081987","volume":"14","author":"J Yoo","year":"2022","unstructured":"Yoo J, Lee J, Cheon M, Woo SK, Ahn MJ, Pyo HR, et al. Predictive value of 18F-FDG PET\/CT using machine learning for pathological response to neoadjuvant concurrent chemoradiotherapy in patients with stage III non-small cell lung cancer. Cancers (Basel). 2022;14:1987.","journal-title":"Cancers (Basel)"},{"key":"13905_CR42","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1007\/s00330-023-10503-8","volume":"34","author":"M Yang","year":"2024","unstructured":"Yang M, Li X, Cai C, Liu C, Ma M, Qu W, et al. [18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicenter study. Eur Radiol. 2024;34:4352\u201363.","journal-title":"Eur Radiol"},{"key":"13905_CR43","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1007\/s00259-023-06394-y","volume":"50","author":"R-D Seban","year":"2023","unstructured":"Seban R-D, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, et al. [18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50:4024\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"13905_CR44","doi-asserted-by":"publisher","first-page":"1067036","DOI":"10.3389\/fimmu.2022.1067036","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Shen L, Wan J, Zhang H, Wu R, Wang J, et al. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation. Front Immunol. 2022;13:1067036.","journal-title":"Front Immunol"},{"key":"13905_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch JS, Cimino-Mathews A, Thompson E, Provencio M, Forde PM, Spicer J, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30:218\u201328.","journal-title":"Nat Med"},{"key":"13905_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2024.05.009","volume":"149","author":"W Sun","year":"2024","unstructured":"Sun W, Qu L, Wu J, Liu X, Wang C, Jiang Y, et al. Percentage and size of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy. Hum Pathol. 2024;149:1\u20139.","journal-title":"Hum Pathol"},{"key":"13905_CR47","doi-asserted-by":"publisher","first-page":"710909","DOI":"10.3389\/fonc.2021.710909","volume":"11","author":"ML Ouyang","year":"2021","unstructured":"Ouyang ML, Wang YR, Deng QS, Zhu YF, Zhao ZH, Wang L, et al. Development and validation of a (18)F-FDG PET-Based radiomics model for evaluating hypermetabolic mediastinal-Hilar lymph nodes in Non-Small-Cell lung cancer. Front Oncol. 2021;11:710909.","journal-title":"Front Oncol"},{"key":"13905_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00432-022-04545-6","volume":"149","author":"M Wang","year":"2023","unstructured":"Wang M, Liu L, Dai Q, Jin M, Huang G. Developing a primary tumor and lymph node 18F-FDG PET\/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC. J Cancer Res Clin Oncol. 2023;149:247\u201361.","journal-title":"J Cancer Res Clin Oncol"},{"key":"13905_CR49","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.7150\/jca.28266","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Mao B, Peng X, Zhou Y, Xia K, Guo H, et al. A comparative study of genetic profiles of key oncogenesis-related genes between primary lesions and matched lymph nodes metastasis in lung cancer. J Cancer. 2019;10:1642\u201350.","journal-title":"J Cancer"},{"key":"13905_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-019-0939-9","volume":"18","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, et al. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctdna sequencing. Mol Cancer. 2019;18:7.","journal-title":"Mol Cancer"},{"key":"13905_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.devcel.2019.04.012","volume":"49","author":"Y Gao","year":"2019","unstructured":"Gao Y, Bado I, Wang H, Zhang W, Rosen JM, Zhang XHF. Metastasis organotropism: redefining the congenial soil. Dev Cell. 2019;49:375\u201391.","journal-title":"Dev Cell"},{"key":"13905_CR52","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.chest.2023.06.038","volume":"164","author":"Y Jin","year":"2023","unstructured":"Jin Y, Kattan MW. Methodologic issues specific to prediction model development and evaluation. Chest. 2023;164:1281\u20139.","journal-title":"Chest"},{"key":"13905_CR53","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.21037\/gs-23-456","volume":"12","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Fu J, Liu Y, Sun H, Fu Q, Zhang S, et al. Prediction of central lymph node metastasis in patients with papillary thyroid microcarcinoma by gradient-boosting decision tree model based on ultrasound radiomics and clinical features. Gland Surg. 2023;12:1722\u201334.","journal-title":"Gland Surg"},{"key":"13905_CR54","doi-asserted-by":"publisher","first-page":"e23584","DOI":"10.1016\/j.heliyon.2023.e23584","volume":"10","author":"P Yasin","year":"2024","unstructured":"Yasin P, Yimit Y, Abliz D, Mardan M, Xu T, Yusufu A, et al. MRI-based interpretable radiomics nomogram for discrimination between Brucella spondylitis and pyogenic spondylitis. Heliyon. 2024;10:e23584.","journal-title":"Heliyon"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13905-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T07:42:27Z","timestamp":1742802147000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13905-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13905"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13905-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Tianjin Medical University Cancer Hospital (Approval number: bc20241623). The need for informed consent was waived by the Ethics Committee of Tianjin Medical University Cancer Hospital due to the retrospective study design. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"520"}}